The round was co-led by Atlas Venture and Pfizer Ventures, with participation from funds managed by Tekla Capital Management LLC, and BioInnovation Capital.
Founded in 2018 by Atlas Venture, Gerhard Koenig and Duane Burnett, PhD, CEO, Senior Vice President, Discovery, Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Its lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
The company’s initial therapeutic focus is a devastating genetically-defined disease called GRN-related frontotemporal dementia (FTD-GRN), which strikes people between the ages of 45 and 65.
FinSMEs
08/11/2019